The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
ADHD Drugs and Cardiovascular Risk
Abstract
On February 9, the Drug Safety and Risk Management Advisory Committee of the FDA voted to recommend a “black-box” warning describing the cardiovascular risks of stimulant drugs used to treat ADHD. Dr. Steven Nissen explains why the advisory committee took decisive action.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The median of these published sudden death rates in children is at 1.2–1.3/100,000/year.”
From European guidelines on managing adverse effects of medication for ADHD (2011) · cites this paper as [99]
In the citing paper
“Sudden death rates range from 0.8 to 8.5/100,000 patient-years [20, 30, 98, 99, 159].”
From European guidelines on managing adverse effects of medication for ADHD (2011) · cites this paper as [99]
In the citing paper
“In contrast to adults, sudden death occurs only rarely in the general paediatric population.”
From European guidelines on managing adverse effects of medication for ADHD (2011) · cites this paper as [99]
In the citing paper
“the frequency of reported sudden death per year of ADHD therapy with methylphenidate, atomoxetine or amfetamines among children was 0.2–0.5/100,000 patient-years [99].”
From European guidelines on managing adverse effects of medication for ADHD (2011) · cites this paper as [99]
In the citing paper
“QTc prolongation (and sudden death and increased heart rate) have been reported with methylphenidate and dexamfetamine [99] and atomoxetine [34].”
From European guidelines on managing adverse effects of medication for ADHD (2011) · cites this paper as [99]
Citations
Cites
Phenylpropanolamine and the Risk of Hemorrhagic Stroke
Kernan, W. N., Viscoli, C. M., Brass, L. M., Broderick, J. P., Brott, T. G., Feldmann, E. G., Morgenstern, L. B., Wilterdink, J. L., & Horwitz, R. I. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012213432501 · Cited by 746
Contraindicated Use of Cisapride
Smalley, W. E., Shatin, D., Wysowski, D. K., Gurwitz, J. H., Andrade, S. E., Goodman, M. J., Chan, K. A., Platt, R. G., Schech, S. D., & Ray, W. A. (2000) · JAMA · doi:10.1001/jama.284.23.3036 · Cited by 253
Wilens, T. E., Hammerness, P. G., Biederman, J., Kwon, A., Spencer, T. J., Clark, S., Scott, M., Podolski, A., Ditterline, J., Morris, M. C., et al. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0215 · Cited by 149
Postmarketing Surveillance of Suicidal Adverse Events with Pediatric Use of Antidepressants
Mosholder, A. D., & Pamer, C. A. (2006) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.16.33 · Cited by 25
Report From the Cardiovascular and Renal Drugs Advisory Committee
Nissen, S. E. (2005) · Circulation · doi:10.1161/circulationaha.105.573105 · Cited by 20
Self-citationThe Relative Safety of Ephedra Compared with Other Herbal Products
Kingston, R. L., & Borron, S. W. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-5_part_1-200309020-00017 · Cited by 6
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–331 of 331
The AD/HD Syndrome as a Group of Biological Disorders
Ziegler, A., Nødland, M., Tveiten, D., & Reichelt, K. L. (2016) · Open Journal of Pediatrics · doi:10.4236/ojped.2016.61005
Drazdowski, T. K. (2016) · VCU Scholars Compass (Virginia Commonwealth University) · doi:10.25772/t7rq-xf10
Caudal nucleus haemorrhage due to dental anaesthesia
Fernández, J. G., Morales, V. G., & Trejo-Gabriel-Galan, J. M. (2010) · Neurología (English Edition) · doi:10.1016/s2173-5808(20)70109-4
Teacher beliefs about children with attention and behavioral difficulties
Stinson, A. M. (2009) · SHAREOK (University of Oklahoma; Oklahoma State University; Central Oklahoma University)
Pediatric Cardiovascular Toxicity
Lowry, J. A. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-416595-3.00016-5
TRATAMIENTO FARMACOLÓGICO DEL TDAH Y LAS COMORBILIDADES
Prince, J. B., & Wilens, T. E. (2010) · Elsevier eBooks · doi:10.1016/b978-84-458-2021-6.00019-1
Chapter 32 – Attention-Deficit/Hyperactivity Disorder in Adolescence
Wolraich, M. (2008) · Elsevier eBooks · doi:10.1016/b978-032304073-0.10032-9
Pharmacological Cosmetic Neurology
Conrad, E. C., & Chatterjee, A. K. (2019) · Cambridge University Press eBooks · doi:10.1017/9781108554350.017
Quanto sono compatibili i farmaci con l'attività atletica
Furlanello, F., Serdoz, L. V., Botrè, F., Accettura, D., Lestuzzi, C., AMBROGGI, L. D., & Cappato, R. (2010) · Giornale italiano di cardiologia · doi:10.1714/660.7702
Anghelescu, I., & Heuser, I. (2008) · Springer eBooks · doi:10.1007/978-3-540-68748-1_35
(2008) · CRC Press eBooks · doi:10.1201/9780849378812.ch3
Sommers‐Flanagan, J., & Sommers‐Flanagan, R. (2015) · Wiley eBooks · doi:10.1002/9781119221623.refs
(2014) · Presses Universitaires de France eBooks · doi:10.3917/puf.gauv.2014.01.0255
Regarding cancer-related fatigue
Revannasiddaiah, S., & Rastogi, M. (2012) · Revista da Associação Médica Brasileira · doi:10.1016/s0104-4230(12)70167-7
Guilé, J.-M. (2012) · Encyclopédie médico-chirurgicale. Psychiatrie · doi:10.1016/s0246-1072(12)53147-0
INCREASED VIGILANCE URGED ON RISK OF PSYCHOSIS WITH ADHD DRUGS
Hurley, D. (2006) · Neurology Today · doi:10.1097/00132985-200605020-00017
EEG neurofeedback for inattention in children with Attention Deficit Hyperactivity Disorder (ADHD)
Clarke, C., Bannon, F. J., & Skokauskas, N. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009207
RetractedRegarding cancer-related fatigue
Revannasiddaiah, S., & Rastogi, M. (2012) · Revista da Associação Médica Brasileira (English Edition) · doi:10.1016/s2255-4823(12)70167-4
Kızılca, Ö., & Baykal, S. (2023) · Namık Kemal Tıp Dergisi · doi:10.4274/nkmj.galenos.2023.38257
Uso do metilfenidato em crianças e adolescentes com TDAH: uma revisão sobre riscos e benefícios
Maurilio, M. M., de Camargo, R. W., & de Bitencourt, R. M. (2023) · Revista Neurociências · doi:10.34024/rnc.2023.v31.14409
Contraindications for Vasoconstrictors
Calatayud, J., & Saraghi, D. M. (2024) · doi:10.1002/9781394180189.ch10
Liao, H.-C., Hsu, C., Lin, F., Gau, S. S., & Wang, C. (2024) · BMJ Paediatrics Open · doi:10.1136/bmjpo-2024-002753
Pentony, M., Ali, Z., Moore, K., McNicholas, F., & James, A. T. (2024) · Cardiology in the Young · doi:10.1017/s1047951124025320
Long-term Safety of Stimulant Medications: Used to Treat Children with ADHD
Lerner, M., & Wigal, T. L. (2008) · Pediatric Annals · doi:10.3928/0090-4481-20080101-05
Onmaz, D. E., Kuz, M., Çetin, F. H., Uçar, H. N., Türkoğlu, S., Coban, R., & Ünlü, A. (2025) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2025.117321
Wait for me: a process account of inhibition
Hammond, S. I. (2007) · Summit (Simon Fraser University)
Levine, B. H. (2008)
Metadata
- Authors
- Nissen, S. E.
- Affiliations
- Cleveland Clinic (US)
- Corresponding author
- Nissen, Steven E.
- ORCID
- Nissen, Steven E.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-04-06
- Volume
- 354
- Issue
- 14
- Pages
- 1445-1448
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2032285255
- Cited by
- 331
- References
- 6
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 3 · 2023: 5 · 2022: 7 · 2021: 4 · 2020: 6 · 2019: 9 · 2018: 10 · 2017: 8 · 2016: 11 · 2015: 14 · 2014: 19 · 2013: 25 · 2012: 28
- FWCI
- 26.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- attention deficit hyperactivity disorder, stimulants, cardiovascular risk, black box warning, drug safety, cardiovascular adverse events
- MeSH terms
- Adult, Central Nervous System Stimulants, Appetite Depressants, Attention Deficit Disorder with Hyperactivity, Cardiovascular Diseases, Child, Death, Sudden, Drug and Narcotic Control, Female, Humans, Male, Phenylpropanolamine, Sympathomimetics, United States, United States Food and Drug Administration, Ephedra
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
